Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

HIV-1 vaccines: let's get physical.

Goonetilleke N, McMichael AJ.

Immunity. 2013 Mar 21;38(3):410-3. doi: 10.1016/j.immuni.2013.02.017.

3.

HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates.

Wille-Reece U, Flynn BJ, Loré K, Koup RA, Kedl RM, Mattapallil JJ, Weiss WR, Roederer M, Seder RA.

Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15190-4. Epub 2005 Oct 11.

4.
5.

Optimizing cellular immunity against HIV-1 Gag and preventing suppression by HIV-1 gp120.

van Montfort T, Sanders RW.

Expert Rev Vaccines. 2012 Oct;11(10):1175-7. doi: 10.1586/erv.12.102.

PMID:
23176650
6.
7.

Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.

Megede JZ, Otten GR, Doe B, Liu H, Srivastava R, Greer C, Legg H, Tang T, Polo JM, Donnelly JJ, Ulmer JB, Barnett SW.

Vaccine. 2006 Apr 5;24(15):2755-63. Epub 2006 Jan 19.

PMID:
16460840
8.
9.

Studies on the cross-clade and cross-species conservation of HIV-1 Gag-specific CD8 and CD4 T cell responses elicited by a clade B DNA/MVA vaccine in macaques.

Amara RR, Sharma S, Patel M, Smith JM, Chennareddi L, Herndon JG, Robinson HL.

Virology. 2005 Mar 30;334(1):124-33.

10.

HIV-1-specific CD8+ T cell responses and viral evolution in women and infants.

Sanchez-Merino V, Nie S, Luzuriaga K.

J Immunol. 2005 Nov 15;175(10):6976-86.

11.

Expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA vaccines.

zur Megede J, Otten GR, Doe B, Liu H, Leung L, Ulmer JB, Donnelly JJ, Barnett SW.

J Virol. 2003 Jun;77(11):6197-207.

12.

Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses.

Tritel M, Stoddard AM, Flynn BJ, Darrah PA, Wu CY, Wille U, Shah JA, Huang Y, Xu L, Betts MR, Nabel GJ, Seder RA.

J Immunol. 2003 Sep 1;171(5):2538-47.

14.

Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized.

Gahéry-Ségard H, Pialoux G, Figueiredo S, Igéa C, Surenaud M, Gaston J, Gras-Masse H, Lévy JP, Guillet JG.

J Virol. 2003 Oct;77(20):11220-31.

15.

Phenotypic and functional characteristics of HIV-specific CD8 T cells and gag sequence variability after autologous dendritic cells based therapeutic vaccine.

López A, van der Lubbe N, Sánchez-Palomino S, Arnedo M, Nomdedeu M, Castro P, Guilà M, Maleno MJ, García F, Gallart T, Gatell JM, Plana M.

Vaccine. 2009 Oct 19;27(44):6166-78. doi: 10.1016/j.vaccine.2009.08.021. Epub 2009 Aug 26.

PMID:
19712765
16.

Regulatory T cell suppression of Gag-specific CD8 T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART.

Macatangay BJ, Szajnik ME, Whiteside TL, Riddler SA, Rinaldo CR.

PLoS One. 2010 Mar 24;5(3):e9852. doi: 10.1371/journal.pone.0009852.

17.

Important contribution of p15 Gag-specific responses to the total Gag-specific CTL responses.

Yu XG, Shang H, Addo MM, Eldridge RL, Phillips MN, Feeney ME, Strick D, Brander C, Goulder PJ, Rosenberg ES, Walker BD, Altfeld M; HIV Study Collaboration.

AIDS. 2002 Feb 15;16(3):321-8.

PMID:
11834942
19.
20.

Avipox-based simian immunodeficiency virus (SIV) vaccines elicit a high frequency of SIV-specific CD4+ and CD8+ T-cell responses in vaccinia-experienced SIVmac251-infected macaques.

Nacsa J, Radaelli A, Edghill-Smith Y, Venzon D, Tsai WP, Morghen Cde G, Panicali D, Tartaglia J, Franchini G.

Vaccine. 2004 Jan 26;22(5-6):597-606.

PMID:
14741150
Items per page

Supplemental Content

Write to the Help Desk